A Study of ELA026 in Participants With Relapsed/Refractory (R/R) T/NK Cell Malignancies (TCMs)

This study is testing a new investigational drug called ELA026 in people with T-cell or NK-cell blood cancers (called T/NK cell malignancies) that have come back or stopped responding to prior treatment. These are rare and aggressive blood cancers, and ELA026 works through a novel mechanism targeting these cancer cells. **You may be eligible if...** - You are 18 years or older - You have a confirmed diagnosis of a T-cell or NK-cell malignancy - Your cancer has relapsed or is refractory (not responding) to prior therapy - For cutaneous T-cell lymphoma: you have tried at least 2 prior systemic treatments - You have measurable disease and are reasonably functional (ECOG ≤2) - Your expected survival is more than 6 months **You may NOT be eligible if...** - A standard approved treatment with established benefit is still available for you - You have significant organ dysfunction - You do not meet other health requirements defined in the protocol Talk to your doctor to see if this trial is right for you.